BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) was upgraded by stock analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Tuesday. BMRN has ...

Though BioMarin’s portfolio comprises eight marketed products, its top line is likely to have been driven by key drugs Voxzogo, Naglazyme and Vimizim. Since its commercial launch in 2021 ...

Commercialization and research and development expenses kept BioMarin in the red for years despite multiple approved products, but we're confident in the durable, profit-generating power of its ...

BioMarin’s revenue largely comes from a few key products, notably Voxzogo and enzyme therapies. It has achieved strong growth through regulatory approvals and market expansion initiatives ...

and potential future products in different areas of therapeutic research and development. Results may differ materially depending on the progress of BioMarin's product programs, actions of ...

Now moving over to our enzyme therapies. Global demand drove strong results across all of BioMarin's marketed products. Double-digit PALYNZIQ revenue growth in the quarter was the result of ...